Try the new, improved Hartford Courant digital edition today
Topics

Gilead Sciences Inc.

Gilead reports $5.8 billion in sales of hepatitis C drug

Gilead reports $5.8 billion in sales of hepatitis C drug

Amid concerns over the high cost of its new treatment for hepatitis C, drugmaker Gilead Sciences Inc. reported $5.8 billion in sales for its blockbuster Sovaldi drug in the first half of 2014. The successful product launch boosted Gilead's second-quarter results released Wednesday, but the drug's price tag of $1,000 per pill continues to upset lawmakers, health insurers and state Medicaid programs worried about the negative effect on healthcare costs. The San Francisco-area company said Wednesday that about 70,000 U.S. patients have been prescribed Sovaldi since it launched in December. A 12-week course of treatment costs about $84,000. This month, two U.S. senators asked...

Loading
69°